Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SIGA Technologies, which specializes in the development of pharmaceutical agents to combat bio-warfare pathogens, has been issued with a fresh Request for Proposal, number 11-100-SOL-00007, by the Biomedical Advanced Research and Development Authority (BARDA), a unit of the US Department of Health and Human Services.
Subscribe to our email newsletter
Through the proposal, BARDA seeks to procure 1.7 million courses of a smallpox antiviral.
The proposal states that the contract would contain an option to obtain up to 12 million additional courses.
Responses to the new proposal are due on 28 February 2011, after BARDA’s previous Request for Proposal on this subject, number 09-35, were cancelled.
SIGA chairman and CEO Eric Rose said the new Request for Proposal confirms the government’s commitment to a robust biodefense and the procurement of meaningful, new medical countermeasures against serious biothreats.
"SIGA intends to respond to this Request for Proposal, and we believe that we are well positioned to meet the government’s needs," Rose said.